168 related articles for article (PubMed ID: 25953308)
1. Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study.
Carulli G; Ottaviano V; Sammuri P; Domenichini C; Guerri V; Rousseau M; Ciancia EM; Ciabatti E; Petrini M
Int J Hematol; 2015 Jul; 102(1):59-66. PubMed ID: 25953308
[TBL] [Abstract][Full Text] [Related]
2. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma.
Douglas VK; Gordon LI; Goolsby CL; White CA; Peterson LC
Am J Clin Pathol; 1999 Dec; 112(6):844-53. PubMed ID: 10587708
[TBL] [Abstract][Full Text] [Related]
3. The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
Babusíková O; Zelezníková T; Mlcáková A; Kusenda J; Stevulová L
Neoplasma; 2005; 52(6):502-9. PubMed ID: 16284697
[TBL] [Abstract][Full Text] [Related]
4. Significant CD5 expression on normal stage 3 hematogones and mature B Lymphocytes in bone marrow.
Fuda FS; Karandikar NJ; Chen W
Am J Clin Pathol; 2009 Nov; 132(5):733-7. PubMed ID: 19846815
[TBL] [Abstract][Full Text] [Related]
5. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
De Angelis F; Tosti ME; Capria S; Russo E; D'Elia GM; Annechini G; Stefanizzi C; Foà R; Pulsoni A
Leuk Res; 2015 Dec; 39(12):1382-8. PubMed ID: 26547259
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
Luminari S; Goldaniga M; Cesaretti M; Orsucci L; Tucci A; Pulsoni A; Salvi F; Arcaini L; Carella AM; Tedeschi A; Pinto A; Stelitano C; Baldini L
Leuk Lymphoma; 2016; 57(4):880-7. PubMed ID: 26379040
[TBL] [Abstract][Full Text] [Related]
7. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes.
Maftoun-Banankhah S; Maleki A; Karandikar NJ; Arbini AA; Fuda FS; Wang HY; Chen W
Am J Clin Pathol; 2008 Feb; 129(2):300-8. PubMed ID: 18208811
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
[TBL] [Abstract][Full Text] [Related]
9. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period.
Lim SH; Esler WV; Zhang Y; Zhang J; Periman PO; Burris C; Townsend M
Leuk Lymphoma; 2008 Jan; 49(1):152-3. PubMed ID: 18203024
[No Abstract] [Full Text] [Related]
10. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
[TBL] [Abstract][Full Text] [Related]
11. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma.
Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Minauchi K; Yamaguchi K; Takeda Y; Sato N; Koizumi K; Mukai M; Koike T
Eur J Haematol; 2006 Sep; 77(3):226-32. PubMed ID: 16923109
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
Matsuda I; Hirota S
Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
14. Multiparameter Flow Cytometry to Detect Hematogones and to Assess B-lymphocyte clonality in Bone Marrow Samples from Patients with Non-Hodgkin Lymphomas.
Carulli G; Ottaviano V; Guerri V; Giuntini S; Sammuri P; Ciancia EM; Azzarà A
Hematol Rep; 2014 Apr; 6(2):5381. PubMed ID: 25013717
[TBL] [Abstract][Full Text] [Related]
15. Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
Santiago V; Lazaryan A; McClune B; McKenna RW; Courville EL
Leuk Lymphoma; 2018 Apr; 59(4):958-966. PubMed ID: 28728454
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
19. Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.
Schirmbeck NG; Mey UJ; Olivieri A; Ko YD; Kaiser U; Flieger D; Witzens-Harig M; Schmidt-Wolf IG
Cancer Invest; 2016 Sep; 34(8):361-72. PubMed ID: 27635469
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune Cytopenias Occurring after Treatment with Chemoimmunotherapy for Non-Hodgkin Lymphomas.
Oka S; Nohgawa M
Acta Haematol; 2019; 141(2):79-83. PubMed ID: 30630159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
